Cannabis Science Updates Second Medical Cannabis Cancer Patient Suffering from Squamous Cell Carcinoma Photo-documents Cannab...
January 19 2012 - 10:55AM
Business Wire
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech
company developing pharmaceutical cannabis (marijuana) products, is
very pleased to announce that the second patient suffering from
basal cell carcinoma (skin cancer) has self-administered cannabis
extracts that appear to have eradicated the cancer.
Following up on the December 12, 2011 news release regarding a
second cancer patient self-administering cannabis extract, this
patient has now given the photo-documented dramatic results of
treatment process. These images can be viewed on the
www.cannabisscience.com website. While the treatment has been
completed and the cancer seems to be gone, Cannabis Science is
waiting for a full biopsy report from the physician to confirm the
patient is free of cancer cells.
Currently it appears that the aforementioned patient will be
able to avoid any surgical procedures such as, standard surgical
excision (Mohs Surgery), and other various types of treatment for
skin cancer, like chemotherapy, radiation, and cryosurgery, by
using the cannabis extracts, just like the first patient mentioned
in our March 9, 2011 news release.
While other treatment options may be effective for many, few
patients would choose to go through a surgical procedure, and
endure the side effects of radiation, or chemotherapy if a simpler
and safer alternative were available. Patients self-administering
cannabis extracts in the convenience of their own home appear to be
effectively resolving their cancerous lesions over a period of a
few weeks to a few months.
Cannabis Science is committed to making cannabis-based medicines
available to the public as rapidly as possible. The Company is
taking multiple approaches to accomplishing this aim in the United
States. The science of cannabinoids has exploded over the past
decade, laying the scientific foundation for the many medicinal
uses of this unique plant. Endoannabinoids are a class of
biologically active lipid compounds produced by all vertebrates
(endocannabinoids) the Cannabis plant (phytocannabinoids), and more
recently patentable synthetic compounds produced by chemists.
Today’s modern peer-reviewed science supports the many historical
uses that were discovered over thousands of years of medicinal use
by herbalists.
Please visit www.cannabisscience.com to view the “Breaking News”
of the successful results and images of the self-administered
cancer treatments.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.